Novo Nordisk pediatric semaglutide obesity trial now active, not recruiting
The 132-week placebo-controlled Phase 3 study enrolls children aged 6 to under 18 with obesity or overweight alongside diet and activity counseling.
PR
By Priya Raman · Science Reporter
Oct 7 08:00 ETSource: ClinicalTrials.gov
The wire
- 01NCT05726227, a Phase 3 Novo Nordisk study of once-weekly subcutaneous semaglutide for weight management in children and adolescents aged 6 to under 18, began 7 July 2023 and is listed as active, not recruiting.
- 02Participants are randomized to semaglutide or placebo for about 2.5 years, with both arms receiving counseling on food choices and physical activity; semaglutide is already approved for adult weight management.
- 03The registry entry reports status only, not results; clinicians weighing pediatric use will need the eventual efficacy and long-term safety readout.
From the source
Read at clinicaltrials.govA Research Study on How Well Semaglutide Helps Children and Teenagers With Excess Body Weight Lose Weight
NCT05726227 · PHASE3 · ACTIVE NOT RECRUITING · Sponsor: Novo Nordisk A/S · Conditions: Obesity.
Source URL https://clinicaltrials.gov/study/NCT05726227
